A new drug combination has been launched in the UK for the treatment of lower urinary tract symptoms.
It is once daily, fixed-dose combination of solifenacin 6mg and tamsulosin 0.4mg, and is the first combination therapy to treat both voiding and storage symptoms linked to prostate enlargement.
The product is available for the treatment of men with moderate to severe storage and voiding symptoms, associated with benign prostatic hyperplasia that do not respond adequately to monotherapy.
Tamsulosin is an alpha-blocker, commonly prescribed to treat lower urinary tract symptoms associated with benign prostatic hyperplasia, while solifenacin is an anti-muscarinic treatment that helps the bladder to hold more urine.
The drug combination is manufactured by Astellas Pharma.
Are you able to Speak Out Safely?
Sign our petition to put pressure on your trust to support an open and transparent NHS.